YESCARTA

BIOLOGICAL3 trials

Sponsors

Masonic Cancer Center, University of Minnesota, Incyte Corporation, Novartis Pharmaceuticals

Conditions

Acute Lymphoblastic LeukemiaAcute Lymphoblastic Leukemia (ALL)Cytokine Release SyndromeDiffuse Large B-Cell Lymphoma (DLBCL)Large B-cell Lymphoma

Phase 2

MT2017-45: CAR-T Cell Therapy for Heme Malignancies

Active, not recruitingNCT03642626

Masonic Cancer Center, University of MinnesotaAcute Lymphoblastic Leukemia, Large B-cell Lymphoma

Start: 2018-12-18End: 2028-06-01Updated: 2026-01-23

A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy

CompletedNCT04071366

Incyte CorporationCytokine Release Syndrome

Start: 2020-02-07End: 2023-08-22Updated: 2024-03-26

Unknown Phase

CAR T Cells Real World Evidence Study Based on the French Hospital Claims Data Source (PMSI)

CompletedNCT05349201

Novartis PharmaceuticalsAcute Lymphoblastic Leukemia (ALL), Diffuse Large B-Cell Lymphoma (DLBCL)

Start: 2020-12-09End: 2021-05-28Updated: 2022-07-01

Related Papers

Itacitinib for the prevention of IEC therapy–associated CRS: results from the 2-part phase 2 INCB 39110-211 study

Blood2025-03-163 citations

Evaluation of Itacitinib Impact on TNFα Levels Following Immune Effector Cell (IEC) Therapy Using PKPD Modeling and Simulation Approaches

Blood2024-11-05

Itacitinib for the Prevention of Immune Effector Cell Therapy-Associated Cytokine Release Syndrome: Results from the Phase 2 Incb 39110-211 Placebo-Controlled Randomized Cohort

Blood2023-11-0216 citations

JAK1 Inhibition during CAR T-Cell Treatment Does Not Affect CAR T-Cell Proliferation, Persistence, or Function

Blood2022-11-1510 citations

Itacitinib (INCB039110), a JAK1 Inhibitor, Reduces Cytokines Associated with Cytokine Release Syndrome Induced by CAR T-cell Therapy

Clinical Cancer Research2020-09-3086 citations